In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora

Anaerobe

Volumn 10, Issue 4, 2004, Pages 205-211

  Finegold, Sydney M ^a,b,c   John, Shahera St ^a   Vu, Ann W ^a   Li, Calida M ^a   Molitoris, Denise ^a   Song, Yuli ^a   Liu, Chengxu ^a   Wexler, Hannah M ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACITRACIN; COTRIMOXAZOLE; METRONIDAZOLE; RAMOPLANIN; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEROIDES; BACTEROIDES FRAGILIS; BILOPHILA; CLOSTRIDIUM; DRUG ACTIVITY; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVOTELLA; PRIORITY JOURNAL; VEILLONELLA;

BACILLI; BACTEROIDES; BACTEROIDES FRAGILIS; BILOPHILA; BRUCELLA; CLOSTRIDIUM; CLOSTRIDIUM BOLTEAE; CLOSTRIDIUM CLOSTRIDIOFORME; NEGIBACTERIA; POSIBACTERIA; PREVOTELLA; VEILLONELLA;

EID: 3543100446     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2004.04.003     Document Type: Article

References (26)

1. Collins L.A., Eliopoulos G.M., Wennersten C.B., Ferraro M.J., Moellering R.C. Jr. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 37:1993;1364-1366
2. Smith T.L., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 340(7):1999;493-501
3. Staphylococcus aureus resistant to vancomycin - United States. MMWR 2002;51(26): 565-7.
4. Skae C.C. The misuse of vancomycin. Pediatr Rev. 24(7):2003;249-250
5. Derlot E, Courvalin P. Mechanisms and implications of glycopeptide resistance in enterococci. Am J Med 1991;91:82S-5S.
6. Ziglam H.M., Finch R.G. Limitations of presently available glycopeptides in the treatment of gram-positive infection. Clin Microbiol Infect. 7(Suppl 4):2001;53-65
7. Noviello S., Ianniello F., Esposito S. In vitro activity of LY333328 (oritavancin) against gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J Antimicrob Chemother. 48:2001;283-286
8. Boger D.L. Vancomycin, teicoplanin, and ramoplanin. synthetic and mechanistic studies Med Res Rev. 21(5):2001;356-381
9. Goldstein E.J.C., et al. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother. 47(1):2003;337-341
10. Lo M-.C., Helm J.S., Sarngadharan G., Pelczer I., Walker S. A new structure for the substrate-binding antibiotic ramoplanin. J Am Chem Soc. 123:2001;8640-8641
11. Reynolds P.E., Somner E.A. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. XVI(8):1990;385-389
12. Somner E.A., Reynolds P.E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother. 34(7):1990;413-419
13. Lo M-.C., et al. A new mechanism of action proposed for ramoplanin. J Am Chem Soc. 122:2000;3540-3541
14. Johnson C.C., Taylor S., Pitsakis P., May P., Levison M.E. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother. 36(10):1992;2342-2345
15. Hassan H., O'Hare M.D., Felmingham D. In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria. Singapore Med J. 31:1990;56-58
16. O'Hare M.D., Ghosh G., Felmingham D., Gruneberg R.N. In-vitro studies of ramoplanin (MDL 62, 198). a novel lipoglycopeptide antimicrobial J Antimicrob Chemother. 25:1990;217-220
17. Citron D.M., et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 47(7):2003;2334-2338
18. Wong M.T., et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis. 33:2001;1476-1482
19. Baden L.R., et al. Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. J Clin Microbiol. 40(4):2002;1160-1163
20. Finegold S.M., Mathisen G.E., George W.L. Hentges D.J. Human intestinal microflora in health and disease. 1983;355-446 Academic Press, New York
21. USD DI. Drug information for the health care professional. vol. 1, March 1998, Sulfonamides, p. 2682; Trimethoprim, p. 2899.
22. USD DI. Drug information for the health care professional. vol. 1, March 1998, Sulfonamides, p. 2682; Trimethoprim, p. 2899.
23. van der Waaij D., Berghuis de Vries J.M. Oral dose and faecal concentration of antibiotics during antibiotic decontamination in mice and in a patient. J Hyg (Camb). 73(2):1974;197-203
24. Jousimies-Somer H.R., et al. Wadsworth-KTL anaerobic bacteriology manual. 2002;Star Publishing Company, Belmont, CA
25. Song Y., Liu C., McTeague M., Finegold S. 16S ribosomal DNA sequence-based analysis of clinically significant gram positive anaerobic cocci. J Clin Microbiol. 41:2003;1363-1369
26. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 5th ed. M11-A5. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001.